Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


EMPA-VISION evaluated the effect of empagliflozin on heart function in patients with chronic heart failure


Phase III randomized, double-blind placebo-controlled trial with two cohorts of patients:

  • HF with reduced ejection fraction (HFrEF)
  • HF with preserved ejection fraction (HFpEF)

Patients were assessed using cutting-edge magnetic resonance imaging (MRI) technology before and after 12 weeks of treatment with empagliflozin or placebo


72 participants were randomized; 59 participants underwent the end of study assessments as COVID-19 restrictions meant participants were unable to attend face-to-face visits from 24 March 2020 onwards.

After 12 weeks of treatment there was no significant difference in the way the heart muscle used energy (measured as the PCr/ATP ratio) between the empagliflozin and placebo groups. This was the case in both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. The results were published in 2023.

Chief investigator

Stefan Neubauer


Rury Holman

Masliza Mahmod

Sponsor Boehringer Ingelheim
Funder Boehringer Ingelheim
Reference number NCT03332212


Ground-breaking phase 3 clinical trial begins in OCMR

A multi-million pound, phase 3 clinical trial (EMPA-VISION) investigating a novel drug that could help failing hearts begins at the Oxford Centre for Clinical Magnetic Resonance Research (OCMR)